Vendor Intelligence Report: Allen Biotechnology Co ABC

Published 3 Jul 2026. 24-page investigative report on who is behind Allen Biotechnology Co ABC: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 68 Finnrick lab tests, Allen Biotechnology Co ABC shows a 75% overall pass rate: 51 pass and 17 fail. That headline masks a sharply uneven catalog. Retatrutide is the defensible line in the current record, while BPC-157 has no passing Finnrick samples and tirzepatide carries the most consequential buyer risk because its failures include severe fill deviations and an identity event. Under stricter purity and fill grading, the buyer read becomes less forgiving.

The investigation also finds a vendor whose public identity is fragile. Allen's strongest historical storefront anchor was its GLP-1 Forum presence, but the live ABC subforum was blocked by Cloudflare during the July field run and the last verifiable archived forum window is February 2026. The Telegram invite remained active, but the group was rebranded as "10 vials", reducing searchable Allen-brand continuity.

Corporate and payment signals do not close the gap. The only surfaced registry lead is a dissolved UK namesake, no active official Allen storefront domain was verified, and an unrelated ABC-branded peptide site creates brand-confusion risk. The report also tracks crypto/stablecoin-only payment rails, US warehouse sale structures, and a late-2025 USPS logistics crisis where buyers carried most of the recourse risk.

Allen is therefore not a blanket yes/no vendor. A buyer already choosing this channel would read retatrutide differently from tirzepatide, tesamorelin, or BPC-157, and would treat batch-specific COA verification and independent testing as part of the purchase cost rather than optional diligence.

Inside the full report:

  • Per-product pass/fail rates, rating trajectories, methodology-divergence charts, and Appendix A lab data for all five tracked products
  • GLP-1 Forum, Wayback, and Cloudflare-access exhibits documenting the ABC subforum and flash-sale trail
  • Telegram/channel matrix covering the rebranded group, direct handle, operator name, email, WhatsApp, and UK Telegram number
  • UK Companies House namesake analysis, domain checks, and the abcpeptides.com brand-confusion control
  • Tirzepatide identity-dispute timeline with Chromate and TrustPointe retest artifacts plus Janoshik portal verification limits
  • US warehouse, crypto-payment, and USPS-crisis analysis tied to buyer recourse

Risk assessment

  • Tirzepatide quality and identity risk — high: 38 Finnrick tests (29 pass / 9 fail; 75.92%) plus severe fill deviations and an identity failure; July 2025 substitution controversy remains unresolved.
  • BPC-157 quality risk — high: 0 pass / 5 fail with a 34.26% Finnrick rating; current evidence supports avoiding this product from Allen unless independently tested.
  • Operational/logistics integrity risk — high: Forum record documents the Sept.–Oct. 2025 USPS crisis, including seized-package and non-performing-tracking complaints, with delayed remediation.
  • Corporate-transparency and brand-confusion risk — high: No verified current legal entity or official domain; UK namesake dissolved in 2020; forum block and Telegram rebrand reduce brand/authenticity signals.
  • Payment/recourse risk — high: Crypto/stablecoin payments only; PayPal and bank transfers explicitly not accepted, leaving no chargeback recourse.
  • Tesamorelin purity/variability risk — medium: 7 pass / 2 fail with a 59.9% Finnrick rating and a documented severe purity outlier.
  • PT-141 evidence-quality risk — medium: Only 4 tests, 3 pass / 1 fail, with a 66.54% Finnrick rating; evidence base is thin and uneven.